These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 29956883)

  • 1. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
    Streicher K; Sridhar S; Kuziora M; Morehouse CA; Higgs BW; Sebastian Y; Groves CJ; Pilataxi F; Brohawn PZ; Herbst R; Ranade K
    Arthritis Rheumatol; 2018 Dec; 70(12):2087-2095. PubMed ID: 29956883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput quantitative histology in systemic sclerosis skin disease using computer vision.
    Correia C; Mawe S; Lofgren S; Marangoni RG; Lee J; Saber R; Aren K; Cheng M; Teaw S; Hoffmann A; Goldberg I; Cowper SE; Khatri P; Hinchcliff M; Mahoney JM
    Arthritis Res Ther; 2020 Mar; 22(1):48. PubMed ID: 32171325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.
    Khanna D; Denton CP; Assassi S; Kuwana M; Allanore Y; Domsic RT; Kleoudis C; Xu J; Csomor E; Seo C; Albulescu M; Tummala R; Al-Mossawi H; Kalyani RN; Del Galdo F
    Clin Exp Rheumatol; 2024 Aug; 42(8):1635-1644. PubMed ID: 39152751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody.
    Wang B; Higgs BW; Chang L; Vainshtein I; Liu Z; Streicher K; Liang M; White WI; Yoo S; Richman L; Jallal B; Roskos L; Yao Y
    Clin Pharmacol Ther; 2013 Jun; 93(6):483-92. PubMed ID: 23511714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The plasma cell signature in autoimmune disease.
    Streicher K; Morehouse CA; Groves CJ; Rajan B; Pilataxi F; Lehmann KP; Brohawn PZ; Higgs BW; McKeever K; Greenberg SA; Fiorentino D; Richman LK; Jallal B; Herbst R; Yao Y; Ranade K
    Arthritis Rheumatol; 2014 Jan; 66(1):173-84. PubMed ID: 24431284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The skin in autoimmune diseases-Unmet needs.
    Kuhn A; Landmann A; Bonsmann G
    Autoimmun Rev; 2016 Oct; 15(10):948-54. PubMed ID: 27481041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status.
    Gheita TA; Sayed S; Azkalany GS; Abaza N; Hammam N; Eissa AH
    Clin Rheumatol; 2018 Mar; 37(3):757-763. PubMed ID: 29076114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
    Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [THE ROLE OF SEMAPHORIN 7A IN SYSTEMIC SCLEROSIS].
    Rimar D; Slobodin G; Rosner I; Rozenbaum M; Kaly L; Boulman N; Jiries N; Awisat A; Vadasz Z
    Harefuah; 2017 Jul; 156(7):418-421. PubMed ID: 28786275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal collagen V deposition in dermis correlates with skin thickening and disease activity in systemic sclerosis.
    Martin P; Teodoro WR; Velosa AP; de Morais J; Carrasco S; Christmann RB; Goldenstein-Schainberg C; Parra ER; Katayama ML; Sotto MN; Capelozzi VL; Yoshinari NH
    Autoimmun Rev; 2012 Sep; 11(11):827-35. PubMed ID: 22406224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: translational association with Hashimoto's thyroiditis.
    Bagnato GL; Roberts WN; Fiorenza A; Arcuri C; Certo R; Trimarchi F; Ruggeri RM; Bagnato GF
    Endocrine; 2016 Feb; 51(2):291-7. PubMed ID: 25994300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
    Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
    J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
    Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y
    Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of angiogenic homeostasis in systemic sclerosis.
    Farouk HM; Hamza SH; El Bakry SA; Youssef SS; Aly IM; Moustafa AA; Assaf NY; El Dakrony AH
    Int J Rheum Dis; 2013 Aug; 16(4):448-54. PubMed ID: 23992267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid effects on myocardial performance in patients with systemic sclerosis.
    Antoniades L; Sfikakis PP; Mavrikakis M
    Clin Exp Rheumatol; 2001; 19(4):431-7. PubMed ID: 11491499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.
    Low AHL; Ng SA; Berrocal V; Brennan B; Chan G; Ng SC; Khanna D
    Int J Rheum Dis; 2019 Jun; 22(6):1036-1040. PubMed ID: 30838791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.